Investorideas.com

Get investor ideas from our AI, cannabis, cleantech, crypto, gaming, mining, sports podcasts - be a guest or sponsor: call 800 665 0411

 


BiotechIndustryStocks.com - A Leading Global Investor Website for Biotech Industry Stocks

BiotechIndustryStocks.com - investing ideas in biotechnology stocks, medical technology, telemedicine, Covid-19

Like Biotech Stocks? View our Biotech Stocks Directory    Get News Alerts on Biotech Stocks


Featured Biotech stocks - Feature Your Company & Product Here

Biotech News

Sorrento's COVID Test Approved in Mexico
June 10, 2021 (Investorideas.com Newswire) This and other recent developments involving Sorrento Therapeutics' pipeline and partners are covered in a Dawson James Securities report.

Kindred Bio Shares Rise 29% after Achieving 100% Survival Rate in Canine Parvovirus Study
June 4, 2021 (Investorideas.com Newswire) Kindred Biosciences Inc. shares reached a new 52-week high after the company reported its parvovirus monoclonal antibody, KIND-030, demonstrated highly positive results in preventing deaths in dogs infected by parvovirus.

Biotech Stock News: Kovo HealthTech Corporation (TSXV: KOVO) Begins Trading on TSX Venture Exchange Today
Vancouver, British Columbia - June 4, 2021 (Newsfile Corp.) (Investorideas.com Newswire) Kovo HealthTech Corporation (TSXV: KOVO) ("Kovo" or the "Company"), a leader in Revenue Cycle Management ("RCM") and healthcare technology, is pleased to announce that its common shares will commence trading on the TSX Venture Exchange (the "TSXV") at the open of the market on June 4, 2021 under the symbol "KOVO".

Biotech Stock News: Izotropic (CSE: IZO) (OTCQB: IZOZF) Updates Timelines for Clinical Study and Fabrication of Initial Izoview Units
Vancouver, British Columbia - June 3, 2021 (Newsfile Corp.) (Investorideas.com Newswire) Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company") a Company commercializing "Izoview", a true 3D, dedicated Breast Computed Tomography (CT) imaging technology for the diagnostic identification of breast cancers, provides updates on the following

Innovative Life Sciences Company Boosts Immune Function in Livestock Without the Use of Antibiotics
June 3, 2021 (Investorideas.com Newswire) Avivagen's OxC-beta™ Livestock products could play a pivotal role in the global mandate to remove all in-feed antibiotics as growth promoters.

Biotech Firm Confirms 100% Accuracy of COVID-19 Mutation Assays
June 3, 2021 (Investorideas.com Newswire) Applied DNA Sciences' SARS-CoV-2 mutation panel and its validation are discussed in a ROTH Capital Partners report.

Analyst: Clinical News, Catalysts Portend 'Rich' Q2/21 for Biopharma
May 27, 2021 (Investorideas.com Newswire) Second-quarter clinical events related to Anavex Life Sciences' pipeline are summarized in a Dawson James Securities report.

Analyst: New Data Show Cancer Therapeutic 'Continues to Deliver Benefit'
May 27, 2021 (Investorideas.com Newswire) Data from two of Oncternal Therapeutics' clinical trials in oncological indications are discussed in an H.C. Wainwright & Co. report.

AI Health Stock News: GBT (OTC: $GTCH) introduces Generation II of its qTerm
San Diego, CA - May 26, 2021 (Investorideas.com Newswire) GBT Technologies Inc. (OTC PINK: GTCH) ("GBT" or the "Company") via GBT Tokenize Corp, completed generation II of its qTerm device. The GEN II release is a second version that includes a series of enhancements that target higher measurement accuracy, reliability and compatibility with a broader spectrum of users usage behavior.

Verastem Shares Rise 25% as FDA Issues Breakthrough Therapy Designation for Ovarian Cancer Drug
May 25, 2021 (Investorideas.com Newswire) Verastem Inc. shares reached a new 52-week high after the company reported its VS-6766 in combination with defactinib was granted breakthrough therapy designation by the FDA for treatment of recurrent low-grade serous ovarian cancer.

Subscribe to Biotech News RSS

Submit Articles   Search More Articles

Biotech Stock ETF's

First Trust NYSE Arca Biotech ETF ( NYSEArca: FBT ) The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology Index(SM). The fund will normally invest at least 90% of its net assets plus the amount of any borrowings for investment purposes in common stocks that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. The fund is non-diversified.

iShares US Healthcare ( NYSEArca: IYH ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Health Care Index (the "underlying index"), which measures the performance of the healthcare sector of the U.S. equity market. The fund is non-diversified.

iShares US Healthcare Providers ( NYSEArca: IHF ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare providers sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Select Health Care Providers Index (the "underlying index"), which measures the performance of the healthcare providers sector of the U.S. equity market. The fund is non-diversified.

iShares US Medical Devices ( NYSEArca: IHI ) The investment seeks to track the investment results of an index composed of U.S. equities in the medical devices sector. The fund seeks to track the investment results of the Dow Jones U.S. Select Medical Equipment Index (the "underlying index"), which measures the performance of the medical equipment sector of the U.S. equity market. The underlying index includes medical equipment companies such as manufacturers and distributors of medical devices such as magnetic resonance imaging (MRI) scanners, prosthetics, pacemakers, X-ray machines, and other non-disposable medical devices. The fund is non-diversified.

iShares Nasdaq Biotechnology ( NasdaqGIDS IBB ) The investment seeks to track the investment results of an index composed of biotechnology and pharmaceutical equities listed on the NASDAQ. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. The underlying index contains securities of NASDAQ® listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by the NASDAQ OMX Group, Inc. The fund is non-diversified.

Market Vectors Biotech ETF ( NYSE MKT:BBH ) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Market Vectors® US Listed Biotech 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index is comprised of common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology sector. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

PowerShares Dynamic Biotech & Genome ETF ( NYSEArca: PBE ) The investment seeks investment results that generally correspond (before fees and expenses) to the price and yield of the Dynamic Biotechnology & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in common stocks of biotechnology companies and genome companies that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of 30 U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.

Related Guest Posts

Buy a guest post on Investorideas.com

Biotech News from Newsfile

Sona Discontinues Clinical Trial for COVID-19 Rapid Saliva Test

This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated April 9, 2021 to its short form base prospectus dated March 31, 2021.

- Encouraging analytical test results did not translate to an ability to consistently detect the virus in clinical samples - Company will focus resources on advancement of other rapid tests and further research with its proprietary gold nanorod technology Halifax, Nova Scotia--(Newsfile Corp. - June 11, 2021) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") a developer of rapid, point-of-care diagnostic tests announces that it is discontinuing its previously announced clinical trial of...

Hemostemix Announces the Closing of a $2,500,000 Convertible Debenture
Calgary, Alberta--(Newsfile Corp. - June 11, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ‎‎(FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce that it closed its previously announced $2,500,000 convertible debenture order from a director of the Company for Debenture Units priced at $1,000 per Unit as detailed below.CLINICAL TRIAL UPDATEHemostemix has obtained a new copy of its clinical trial data base from a former service provider who originally activated the clinical trial and who...

Entheon Biomedical's Wholly-Owned Subsidiary, HaluGen Life Sciences, Psychedelics Genetic Test Kit Now Available for Sale in US

HaluGen Life Sciences' test evaluates an individual's overall sensitivity and risk profile associated with psychedelic-assisted therapy

Vancouver, British Columbia--(Newsfile Corp. - June 10, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced its Psychedelics Genetic Test Kit, developed by its wholly-owned subsidiary, HaluGen Life Sciences Inc. ("HaluGen"), is now available for sale in the United States. The Psychedelics Genetic Test Kit, a first of its kind, was designed and commercialized by HaluGen, and...

NervGen Pharma Enters into Research Agreement with Sylics to Study NVG-291 in Alzheimer's Disease Models

NervGen Preparing for Upcoming Phase 1b Clinical Trial in Alzheimer's Disease

Vancouver, British Columbia--(Newsfile Corp. - June 10, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, announced today it has entered into a research agreement with Sylics Contract Research ("Sylics"), a contract research organization specializing in testing novel therapies in the field of neurosciences, to study the effects of NVG-291 in mouse models of...

Annovis Bio to Present at 2021 BIO Digital
Berwyn, Pennsylvania--(Newsfile Corp. - June 10, 2021) - Annovis Bio, Inc. (NYSE American: ANVS), ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced its participation in 2021 BIO Digital, the premier biotech event, taking place online June 10-11 & 14-18, 2021.A corporate presentation by Maria L. Maccecchini, Ph.D., CEO of Annovis Bio, will be available to registered attendees beginning at 9:00 a.m....

Subscribe to Biotech News